RisserWL, RisserJMH.The incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis: a structured review.Int J STD AIDS2007; 18: 727–31.
2.
MorreSA, van den BruleAJ, RozendaalL.The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up.Int J STD AIDS2002; 13: 12–8.
3.
ScholesD, StergachisA, HeidrichFE, AndrillaH, HolmesKK, StammWE.Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection.N Engl J Med1996; 334: 1362–6.
4.
OstergaardL, AndersenB, OlesenF, MollerJK.Efficacy of home sampling for screening of Chlamydia trachomatis: randomised study.BMJ1998; 317: 26–7.
5.
OstergaardL, AndersenB, MollerJK, OlesenF.Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study.Clin Infect Dis2000; 31: 951–7.
6.
TaitIA, DuthieSJ, Taylor-RobinsonD.Silent upper genital tract chlamydial infection and disease in women.Int J STD AIDS1997; 8: 329–31.
7.
Van ValkengoedIGM, MorreSA, van den BruleAJC.Over-estimation of complication rates in evaluations of Chlamydia trachomatis screening programmes - implications for cost-effectiveness analyses.Int J Epidemiol2004; 33: 416–23.
8.
LowN.Screening programmes for chlamydial infection: when will we ever learn?BMJ2007; 334: 725–8.
9.
BoekeAJP, van BergenJEAM, MorreSA, van EverdingenJJE.The risk of pelvic inflammatory disease associated with urogenital infection with Chlamydia trachomatis; literature review.Ned Tijdschr Geneeskd2005; 149: 878–84.
